nodes	percent_of_prediction	percent_of_DWPC	metapath
Droperidol—Haloperidol—CBR1—prostate cancer	0.0103	0.378	CrCbGaD
Droperidol—Anaphylactic shock—Estrone—prostate cancer	0.00405	0.00513	CcSEcCtD
Droperidol—Chills—Cabazitaxel—prostate cancer	0.004	0.00506	CcSEcCtD
Droperidol—Hypertension—Nilutamide—prostate cancer	0.00398	0.00504	CcSEcCtD
Droperidol—Hypertension—Flutamide—prostate cancer	0.00396	0.00502	CcSEcCtD
Droperidol—Angioedema—Estradiol valerate/Dienogest—prostate cancer	0.00396	0.00501	CcSEcCtD
Droperidol—Anxiety—Flutamide—prostate cancer	0.00389	0.00493	CcSEcCtD
Droperidol—Palpitations—Estradiol valerate/Dienogest—prostate cancer	0.00383	0.00485	CcSEcCtD
Droperidol—Gynaecomastia—Estradiol—prostate cancer	0.00376	0.00476	CcSEcCtD
Droperidol—Torsade de pointes—Capecitabine—prostate cancer	0.00373	0.00473	CcSEcCtD
Droperidol—Shock—Nilutamide—prostate cancer	0.0037	0.00469	CcSEcCtD
Droperidol—HTR2A—urine—prostate cancer	0.00368	0.177	CbGeAlD
Droperidol—Anxiety—Estradiol valerate/Dienogest—prostate cancer	0.00367	0.00465	CcSEcCtD
Droperidol—Palpitations—Degarelix—prostate cancer	0.00364	0.00461	CcSEcCtD
Droperidol—Depression—Ethinyl Estradiol—prostate cancer	0.00359	0.00455	CcSEcCtD
Droperidol—Hypertension—Degarelix—prostate cancer	0.00355	0.0045	CcSEcCtD
Droperidol—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.00353	0.00448	CcSEcCtD
Droperidol—Chills—Bicalutamide—prostate cancer	0.00343	0.00434	CcSEcCtD
Droperidol—Anaphylactic shock—Degarelix—prostate cancer	0.00336	0.00426	CcSEcCtD
Droperidol—Hypertension—Cabazitaxel—prostate cancer	0.00335	0.00424	CcSEcCtD
Droperidol—Somnolence—Flutamide—prostate cancer	0.00333	0.00422	CcSEcCtD
Droperidol—Anxiety—Cabazitaxel—prostate cancer	0.00329	0.00417	CcSEcCtD
Droperidol—Body temperature increased—Abiraterone—prostate cancer	0.00325	0.00412	CcSEcCtD
Droperidol—Bronchospasm—Conjugated Estrogens—prostate cancer	0.00324	0.0041	CcSEcCtD
Droperidol—Hypotension—Degarelix—prostate cancer	0.00314	0.00398	CcSEcCtD
Droperidol—Tachycardia—Cabazitaxel—prostate cancer	0.00309	0.00391	CcSEcCtD
Droperidol—Amenorrhoea—Docetaxel—prostate cancer	0.00308	0.0039	CcSEcCtD
Droperidol—Angioedema—Bicalutamide—prostate cancer	0.00304	0.00385	CcSEcCtD
Droperidol—Hyperglycaemia—Goserelin—prostate cancer	0.003	0.0038	CcSEcCtD
Droperidol—Syncope—Bicalutamide—prostate cancer	0.00298	0.00378	CcSEcCtD
Droperidol—Body temperature increased—Nilutamide—prostate cancer	0.00297	0.00377	CcSEcCtD
Droperidol—Hyperglycaemia—Conjugated Estrogens—prostate cancer	0.00297	0.00376	CcSEcCtD
Droperidol—Drowsiness—Goserelin—prostate cancer	0.00296	0.00375	CcSEcCtD
Droperidol—Hypotension—Cabazitaxel—prostate cancer	0.00296	0.00375	CcSEcCtD
Droperidol—Depression—Goserelin—prostate cancer	0.00295	0.00374	CcSEcCtD
Droperidol—Depression—Conjugated Estrogens—prostate cancer	0.00293	0.00371	CcSEcCtD
Droperidol—Loss of consciousness—Bicalutamide—prostate cancer	0.00292	0.0037	CcSEcCtD
Droperidol—Hypertension—Bicalutamide—prostate cancer	0.00287	0.00364	CcSEcCtD
Droperidol—Anxiety—Bicalutamide—prostate cancer	0.00282	0.00358	CcSEcCtD
Droperidol—Blood pressure increased—Docetaxel—prostate cancer	0.0027	0.00343	CcSEcCtD
Droperidol—Dizziness—Estrone—prostate cancer	0.00268	0.00339	CcSEcCtD
Droperidol—Rash—Estramustine—prostate cancer	0.00267	0.00339	CcSEcCtD
Droperidol—Shock—Bicalutamide—prostate cancer	0.00267	0.00338	CcSEcCtD
Droperidol—Dermatitis—Estramustine—prostate cancer	0.00267	0.00338	CcSEcCtD
Droperidol—Body temperature increased—Degarelix—prostate cancer	0.00266	0.00337	CcSEcCtD
Droperidol—Amenorrhoea—Prednisone—prostate cancer	0.00265	0.00336	CcSEcCtD
Droperidol—Blood pressure increased—Capecitabine—prostate cancer	0.00262	0.00332	CcSEcCtD
Droperidol—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.0026	0.0033	CcSEcCtD
Droperidol—Rash—Abiraterone—prostate cancer	0.0026	0.00329	CcSEcCtD
Droperidol—Dermatitis—Abiraterone—prostate cancer	0.00259	0.00329	CcSEcCtD
Droperidol—Bronchospasm—Estradiol—prostate cancer	0.00259	0.00328	CcSEcCtD
Droperidol—Domperidone—CYP3A5—prostate cancer	0.00257	0.0942	CrCbGaD
Droperidol—Angioedema—Ethinyl Estradiol—prostate cancer	0.00257	0.00326	CcSEcCtD
Droperidol—Rash—Estrone—prostate cancer	0.00255	0.00323	CcSEcCtD
Droperidol—Dermatitis—Estrone—prostate cancer	0.00255	0.00323	CcSEcCtD
Droperidol—Body temperature increased—Cabazitaxel—prostate cancer	0.0025	0.00317	CcSEcCtD
Droperidol—Dizziness—Nilutamide—prostate cancer	0.00249	0.00315	CcSEcCtD
Droperidol—Dizziness—Flutamide—prostate cancer	0.00248	0.00314	CcSEcCtD
Droperidol—Hypersensitivity—Degarelix—prostate cancer	0.00248	0.00314	CcSEcCtD
Droperidol—Ventricular arrhythmia—Epirubicin—prostate cancer	0.00246	0.00312	CcSEcCtD
Droperidol—Somnolence—Bicalutamide—prostate cancer	0.00241	0.00306	CcSEcCtD
Droperidol—Anxiety—Ethinyl Estradiol—prostate cancer	0.00239	0.00302	CcSEcCtD
Droperidol—Chills—Goserelin—prostate cancer	0.00239	0.00302	CcSEcCtD
Droperidol—Hyperglycaemia—Estradiol—prostate cancer	0.00238	0.00301	CcSEcCtD
Droperidol—Rash—Nilutamide—prostate cancer	0.00237	0.003	CcSEcCtD
Droperidol—Dermatitis—Nilutamide—prostate cancer	0.00237	0.003	CcSEcCtD
Droperidol—Rash—Flutamide—prostate cancer	0.00236	0.00299	CcSEcCtD
Droperidol—Dermatitis—Flutamide—prostate cancer	0.00236	0.00299	CcSEcCtD
Droperidol—Depression—Estradiol—prostate cancer	0.00234	0.00297	CcSEcCtD
Droperidol—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00234	0.00296	CcSEcCtD
Droperidol—Hypersensitivity—Cabazitaxel—prostate cancer	0.00233	0.00295	CcSEcCtD
Droperidol—Ventricular arrhythmia—Doxorubicin—prostate cancer	0.00228	0.00289	CcSEcCtD
Droperidol—Cardiac arrest—Etoposide—prostate cancer	0.00225	0.00284	CcSEcCtD
Droperidol—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00223	0.00282	CcSEcCtD
Droperidol—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00223	0.00282	CcSEcCtD
Droperidol—Dizziness—Degarelix—prostate cancer	0.00222	0.00282	CcSEcCtD
Droperidol—Hyperglycaemia—Mitoxantrone—prostate cancer	0.00221	0.0028	CcSEcCtD
Droperidol—Drowsiness—Mitoxantrone—prostate cancer	0.00219	0.00277	CcSEcCtD
Droperidol—Pimozide—CYP3A5—prostate cancer	0.00215	0.0787	CrCbGaD
Droperidol—Body temperature increased—Bicalutamide—prostate cancer	0.00215	0.00272	CcSEcCtD
Droperidol—Rash—Degarelix—prostate cancer	0.00212	0.00268	CcSEcCtD
Droperidol—Dermatitis—Degarelix—prostate cancer	0.00212	0.00268	CcSEcCtD
Droperidol—Angioedema—Conjugated Estrogens—prostate cancer	0.00209	0.00265	CcSEcCtD
Droperidol—Dizziness—Cabazitaxel—prostate cancer	0.00209	0.00265	CcSEcCtD
Droperidol—Amenorrhoea—Epirubicin—prostate cancer	0.00208	0.00263	CcSEcCtD
Droperidol—Syncope—Conjugated Estrogens—prostate cancer	0.00206	0.0026	CcSEcCtD
Droperidol—Palpitations—Goserelin—prostate cancer	0.00205	0.00259	CcSEcCtD
Droperidol—ADRA1A—prostate gland—prostate cancer	0.00204	0.0983	CbGeAlD
Droperidol—Palpitations—Conjugated Estrogens—prostate cancer	0.00203	0.00257	CcSEcCtD
Droperidol—Loss of consciousness—Conjugated Estrogens—prostate cancer	0.00202	0.00255	CcSEcCtD
Droperidol—Bronchospasm—Etoposide—prostate cancer	0.00201	0.00254	CcSEcCtD
Droperidol—Hypersensitivity—Bicalutamide—prostate cancer	0.002	0.00253	CcSEcCtD
Droperidol—Hypertension—Goserelin—prostate cancer	0.002	0.00253	CcSEcCtD
Droperidol—KCNH2—prostate gland—prostate cancer	0.00197	0.095	CbGeAlD
Droperidol—Anxiety—Goserelin—prostate cancer	0.00196	0.00249	CcSEcCtD
Droperidol—Haloperidol—CYP3A5—prostate cancer	0.00196	0.0718	CrCbGaD
Droperidol—Anxiety—Conjugated Estrogens—prostate cancer	0.00195	0.00246	CcSEcCtD
Droperidol—Amenorrhoea—Doxorubicin—prostate cancer	0.00192	0.00243	CcSEcCtD
Droperidol—Chills—Estradiol—prostate cancer	0.00189	0.0024	CcSEcCtD
Droperidol—Anaphylactic shock—Goserelin—prostate cancer	0.00189	0.00239	CcSEcCtD
Droperidol—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.00187	0.00237	CcSEcCtD
Droperidol—Shock—Goserelin—prostate cancer	0.00186	0.00235	CcSEcCtD
Droperidol—Tachycardia—Goserelin—prostate cancer	0.00184	0.00234	CcSEcCtD
Droperidol—Shock—Conjugated Estrogens—prostate cancer	0.00184	0.00233	CcSEcCtD
Droperidol—Tachycardia—Conjugated Estrogens—prostate cancer	0.00183	0.00231	CcSEcCtD
Droperidol—Ventricular tachycardia—Epirubicin—prostate cancer	0.00182	0.00231	CcSEcCtD
Droperidol—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.00181	0.0023	CcSEcCtD
Droperidol—Cardiac arrest—Capecitabine—prostate cancer	0.00181	0.00229	CcSEcCtD
Droperidol—Dizziness—Bicalutamide—prostate cancer	0.0018	0.00227	CcSEcCtD
Droperidol—Fenbufen—PTGS2—prostate cancer	0.00179	0.0657	CrCbGaD
Droperidol—Hypotension—Goserelin—prostate cancer	0.00177	0.00224	CcSEcCtD
Droperidol—Chills—Mitoxantrone—prostate cancer	0.00176	0.00223	CcSEcCtD
Droperidol—Hypotension—Conjugated Estrogens—prostate cancer	0.00175	0.00221	CcSEcCtD
Droperidol—Rash—Bicalutamide—prostate cancer	0.00171	0.00217	CcSEcCtD
Droperidol—Dermatitis—Bicalutamide—prostate cancer	0.00171	0.00217	CcSEcCtD
Droperidol—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00169	0.00214	CcSEcCtD
Droperidol—Ventricular tachycardia—Doxorubicin—prostate cancer	0.00169	0.00214	CcSEcCtD
Droperidol—Somnolence—Goserelin—prostate cancer	0.00168	0.00213	CcSEcCtD
Droperidol—Angioedema—Estradiol—prostate cancer	0.00168	0.00212	CcSEcCtD
Droperidol—KCNH2—seminal vesicle—prostate cancer	0.00167	0.0803	CbGeAlD
Droperidol—Bronchospasm—Docetaxel—prostate cancer	0.00167	0.00211	CcSEcCtD
Droperidol—Somnolence—Conjugated Estrogens—prostate cancer	0.00166	0.00211	CcSEcCtD
Droperidol—Syncope—Estradiol—prostate cancer	0.00165	0.00208	CcSEcCtD
Droperidol—Palpitations—Estradiol—prostate cancer	0.00162	0.00205	CcSEcCtD
Droperidol—Bronchospasm—Capecitabine—prostate cancer	0.00162	0.00205	CcSEcCtD
Droperidol—Loss of consciousness—Estradiol—prostate cancer	0.00161	0.00204	CcSEcCtD
Droperidol—Cardiac arrest—Prednisone—prostate cancer	0.00161	0.00204	CcSEcCtD
Droperidol—Hypertension—Estradiol—prostate cancer	0.00158	0.00201	CcSEcCtD
Droperidol—Anxiety—Estradiol—prostate cancer	0.00156	0.00197	CcSEcCtD
Droperidol—Dizziness—Ethinyl Estradiol—prostate cancer	0.00152	0.00192	CcSEcCtD
Droperidol—ADRA1A—epithelium—prostate cancer	0.0015	0.0723	CbGeAlD
Droperidol—Anaphylactic shock—Estradiol—prostate cancer	0.0015	0.0019	CcSEcCtD
Droperidol—Body temperature increased—Goserelin—prostate cancer	0.00149	0.00189	CcSEcCtD
Droperidol—Hyperglycaemia—Capecitabine—prostate cancer	0.00148	0.00188	CcSEcCtD
Droperidol—Body temperature increased—Conjugated Estrogens—prostate cancer	0.00148	0.00187	CcSEcCtD
Droperidol—Pimozide—CYP2E1—prostate cancer	0.00148	0.0541	CrCbGaD
Droperidol—Hypertension—Mitoxantrone—prostate cancer	0.00148	0.00187	CcSEcCtD
Droperidol—Shock—Estradiol—prostate cancer	0.00147	0.00187	CcSEcCtD
Droperidol—Chills—Etoposide—prostate cancer	0.00147	0.00186	CcSEcCtD
Droperidol—Pimozide—CYP2C19—prostate cancer	0.00146	0.0536	CrCbGaD
Droperidol—Tachycardia—Estradiol—prostate cancer	0.00146	0.00185	CcSEcCtD
Droperidol—Depression—Capecitabine—prostate cancer	0.00146	0.00185	CcSEcCtD
Droperidol—Anxiety—Mitoxantrone—prostate cancer	0.00145	0.00184	CcSEcCtD
Droperidol—Rash—Ethinyl Estradiol—prostate cancer	0.00145	0.00183	CcSEcCtD
Droperidol—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00145	0.00183	CcSEcCtD
Droperidol—Anaphylactic shock—Mitoxantrone—prostate cancer	0.0014	0.00177	CcSEcCtD
Droperidol—ADRA1A—renal system—prostate cancer	0.00139	0.067	CbGeAlD
Droperidol—Hypersensitivity—Goserelin—prostate cancer	0.00139	0.00176	CcSEcCtD
Droperidol—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00138	0.00175	CcSEcCtD
Droperidol—Shock—Mitoxantrone—prostate cancer	0.00137	0.00174	CcSEcCtD
Droperidol—Tachycardia—Mitoxantrone—prostate cancer	0.00136	0.00173	CcSEcCtD
Droperidol—KCNH2—renal system—prostate cancer	0.00135	0.0647	CbGeAlD
Droperidol—Haloperidol—CYP2C19—prostate cancer	0.00133	0.0489	CrCbGaD
Droperidol—Somnolence—Estradiol—prostate cancer	0.00133	0.00169	CcSEcCtD
Droperidol—Haloperidol—CYP1A1—prostate cancer	0.00133	0.0487	CrCbGaD
Droperidol—KCNH2—urethra—prostate cancer	0.00132	0.0636	CbGeAlD
Droperidol—Hyperglycaemia—Prednisone—prostate cancer	0.00132	0.00167	CcSEcCtD
Droperidol—Hypotension—Mitoxantrone—prostate cancer	0.0013	0.00165	CcSEcCtD
Droperidol—Depression—Prednisone—prostate cancer	0.0013	0.00165	CcSEcCtD
Droperidol—Cardiac arrest—Epirubicin—prostate cancer	0.00126	0.00159	CcSEcCtD
Droperidol—Loss of consciousness—Etoposide—prostate cancer	0.00125	0.00158	CcSEcCtD
Droperidol—Dizziness—Goserelin—prostate cancer	0.00125	0.00158	CcSEcCtD
Droperidol—Somnolence—Mitoxantrone—prostate cancer	0.00124	0.00157	CcSEcCtD
Droperidol—Dizziness—Conjugated Estrogens—prostate cancer	0.00124	0.00157	CcSEcCtD
Droperidol—Hypertension—Etoposide—prostate cancer	0.00123	0.00156	CcSEcCtD
Droperidol—Chills—Docetaxel—prostate cancer	0.00122	0.00154	CcSEcCtD
Droperidol—Rash—Goserelin—prostate cancer	0.00119	0.00151	CcSEcCtD
Droperidol—Dermatitis—Goserelin—prostate cancer	0.00119	0.00151	CcSEcCtD
Droperidol—Body temperature increased—Estradiol—prostate cancer	0.00118	0.0015	CcSEcCtD
Droperidol—Rash—Conjugated Estrogens—prostate cancer	0.00118	0.00149	CcSEcCtD
Droperidol—Chills—Capecitabine—prostate cancer	0.00118	0.00149	CcSEcCtD
Droperidol—Dermatitis—Conjugated Estrogens—prostate cancer	0.00118	0.00149	CcSEcCtD
Droperidol—Hallucination—Prednisone—prostate cancer	0.00116	0.00148	CcSEcCtD
Droperidol—Cardiac arrest—Doxorubicin—prostate cancer	0.00116	0.00148	CcSEcCtD
Droperidol—Anaphylactic shock—Etoposide—prostate cancer	0.00116	0.00147	CcSEcCtD
Droperidol—Tachycardia—Etoposide—prostate cancer	0.00113	0.00144	CcSEcCtD
Droperidol—Domperidone—CYP3A4—prostate cancer	0.00111	0.0408	CrCbGaD
Droperidol—Hypersensitivity—Estradiol—prostate cancer	0.0011	0.0014	CcSEcCtD
Droperidol—Body temperature increased—Mitoxantrone—prostate cancer	0.0011	0.0014	CcSEcCtD
Droperidol—Hypotension—Etoposide—prostate cancer	0.00108	0.00137	CcSEcCtD
Droperidol—Syncope—Docetaxel—prostate cancer	0.00106	0.00134	CcSEcCtD
Droperidol—Palpitations—Docetaxel—prostate cancer	0.00104	0.00132	CcSEcCtD
Droperidol—Loss of consciousness—Docetaxel—prostate cancer	0.00104	0.00132	CcSEcCtD
Droperidol—Hyperglycaemia—Epirubicin—prostate cancer	0.00103	0.00131	CcSEcCtD
Droperidol—Somnolence—Etoposide—prostate cancer	0.00103	0.00131	CcSEcCtD
Droperidol—Hypersensitivity—Mitoxantrone—prostate cancer	0.00103	0.0013	CcSEcCtD
Droperidol—Syncope—Capecitabine—prostate cancer	0.00103	0.0013	CcSEcCtD
Droperidol—Hypertension—Docetaxel—prostate cancer	0.00102	0.00129	CcSEcCtD
Droperidol—Drowsiness—Epirubicin—prostate cancer	0.00102	0.00129	CcSEcCtD
Droperidol—KCNH2—bone marrow—prostate cancer	0.00102	0.0489	CbGeAlD
Droperidol—Palpitations—Capecitabine—prostate cancer	0.00101	0.00128	CcSEcCtD
Droperidol—Loss of consciousness—Capecitabine—prostate cancer	0.00101	0.00127	CcSEcCtD
Droperidol—Dizziness—Estradiol—prostate cancer	0.00099	0.00125	CcSEcCtD
Droperidol—Hypertension—Capecitabine—prostate cancer	0.000988	0.00125	CcSEcCtD
Droperidol—Anxiety—Capecitabine—prostate cancer	0.000971	0.00123	CcSEcCtD
Droperidol—HTR2A—epithelium—prostate cancer	0.000971	0.0467	CbGeAlD
Droperidol—Anaphylactic shock—Docetaxel—prostate cancer	0.000965	0.00122	CcSEcCtD
Droperidol—Hyperglycaemia—Doxorubicin—prostate cancer	0.000955	0.00121	CcSEcCtD
Droperidol—Shock—Docetaxel—prostate cancer	0.000949	0.0012	CcSEcCtD
Droperidol—Rash—Estradiol—prostate cancer	0.000944	0.0012	CcSEcCtD
Droperidol—Drowsiness—Doxorubicin—prostate cancer	0.000944	0.0012	CcSEcCtD
Droperidol—Dermatitis—Estradiol—prostate cancer	0.000943	0.0012	CcSEcCtD
Droperidol—Tachycardia—Docetaxel—prostate cancer	0.000941	0.00119	CcSEcCtD
Droperidol—Angioedema—Prednisone—prostate cancer	0.000931	0.00118	CcSEcCtD
Droperidol—Pimozide—CYP3A4—prostate cancer	0.00093	0.0341	CrCbGaD
Droperidol—Shock—Capecitabine—prostate cancer	0.000919	0.00116	CcSEcCtD
Droperidol—Body temperature increased—Etoposide—prostate cancer	0.000917	0.00116	CcSEcCtD
Droperidol—Syncope—Prednisone—prostate cancer	0.000914	0.00116	CcSEcCtD
Droperidol—Tachycardia—Capecitabine—prostate cancer	0.000911	0.00115	CcSEcCtD
Droperidol—Hypotension—Docetaxel—prostate cancer	0.000901	0.00114	CcSEcCtD
Droperidol—HTR2A—renal system—prostate cancer	0.0009	0.0433	CbGeAlD
Droperidol—Loss of consciousness—Prednisone—prostate cancer	0.000896	0.00113	CcSEcCtD
Droperidol—DRD2—testis—prostate cancer	0.000882	0.0425	CbGeAlD
Droperidol—Hypertension—Prednisone—prostate cancer	0.00088	0.00111	CcSEcCtD
Droperidol—Rash—Mitoxantrone—prostate cancer	0.00088	0.00111	CcSEcCtD
Droperidol—Dermatitis—Mitoxantrone—prostate cancer	0.000879	0.00111	CcSEcCtD
Droperidol—Hypotension—Capecitabine—prostate cancer	0.000873	0.00111	CcSEcCtD
Droperidol—KCNH2—testis—prostate cancer	0.000869	0.0418	CbGeAlD
Droperidol—Anxiety—Prednisone—prostate cancer	0.000865	0.0011	CcSEcCtD
Droperidol—Somnolence—Docetaxel—prostate cancer	0.000857	0.00109	CcSEcCtD
Droperidol—Hypersensitivity—Etoposide—prostate cancer	0.000855	0.00108	CcSEcCtD
Droperidol—Haloperidol—CYP3A4—prostate cancer	0.000849	0.0311	CrCbGaD
Droperidol—Anaphylactic shock—Prednisone—prostate cancer	0.000832	0.00105	CcSEcCtD
Droperidol—Chills—Epirubicin—prostate cancer	0.000822	0.00104	CcSEcCtD
Droperidol—Shock—Prednisone—prostate cancer	0.000818	0.00104	CcSEcCtD
Droperidol—Tachycardia—Prednisone—prostate cancer	0.000812	0.00103	CcSEcCtD
Droperidol—Dizziness—Etoposide—prostate cancer	0.000767	0.000972	CcSEcCtD
Droperidol—Body temperature increased—Docetaxel—prostate cancer	0.000762	0.000966	CcSEcCtD
Droperidol—Chills—Doxorubicin—prostate cancer	0.00076	0.000963	CcSEcCtD
Droperidol—Body temperature increased—Capecitabine—prostate cancer	0.000738	0.000935	CcSEcCtD
Droperidol—Rash—Etoposide—prostate cancer	0.000732	0.000927	CcSEcCtD
Droperidol—Dermatitis—Etoposide—prostate cancer	0.000731	0.000926	CcSEcCtD
Droperidol—Syncope—Epirubicin—prostate cancer	0.000715	0.000906	CcSEcCtD
Droperidol—Hypersensitivity—Docetaxel—prostate cancer	0.000711	0.0009	CcSEcCtD
Droperidol—Palpitations—Epirubicin—prostate cancer	0.000704	0.000892	CcSEcCtD
Droperidol—Loss of consciousness—Epirubicin—prostate cancer	0.000701	0.000888	CcSEcCtD
Droperidol—Hypertension—Epirubicin—prostate cancer	0.000688	0.000872	CcSEcCtD
Droperidol—Hypersensitivity—Capecitabine—prostate cancer	0.000688	0.000872	CcSEcCtD
Droperidol—Anxiety—Epirubicin—prostate cancer	0.000676	0.000857	CcSEcCtD
Droperidol—Syncope—Doxorubicin—prostate cancer	0.000661	0.000838	CcSEcCtD
Droperidol—Body temperature increased—Prednisone—prostate cancer	0.000658	0.000833	CcSEcCtD
Droperidol—Palpitations—Doxorubicin—prostate cancer	0.000652	0.000826	CcSEcCtD
Droperidol—Anaphylactic shock—Epirubicin—prostate cancer	0.000651	0.000824	CcSEcCtD
Droperidol—Loss of consciousness—Doxorubicin—prostate cancer	0.000648	0.000821	CcSEcCtD
Droperidol—Shock—Epirubicin—prostate cancer	0.00064	0.000811	CcSEcCtD
Droperidol—Dizziness—Docetaxel—prostate cancer	0.000638	0.000808	CcSEcCtD
Droperidol—Hypertension—Doxorubicin—prostate cancer	0.000637	0.000807	CcSEcCtD
Droperidol—Tachycardia—Epirubicin—prostate cancer	0.000635	0.000804	CcSEcCtD
Droperidol—KCNH2—lymph node—prostate cancer	0.00063	0.0303	CbGeAlD
Droperidol—Anxiety—Doxorubicin—prostate cancer	0.000626	0.000793	CcSEcCtD
Droperidol—Dizziness—Capecitabine—prostate cancer	0.000618	0.000782	CcSEcCtD
Droperidol—Hypersensitivity—Prednisone—prostate cancer	0.000613	0.000776	CcSEcCtD
Droperidol—Rash—Docetaxel—prostate cancer	0.000608	0.00077	CcSEcCtD
Droperidol—Hypotension—Epirubicin—prostate cancer	0.000608	0.00077	CcSEcCtD
Droperidol—Dermatitis—Docetaxel—prostate cancer	0.000608	0.00077	CcSEcCtD
Droperidol—Anaphylactic shock—Doxorubicin—prostate cancer	0.000602	0.000763	CcSEcCtD
Droperidol—Shock—Doxorubicin—prostate cancer	0.000592	0.00075	CcSEcCtD
Droperidol—Rash—Capecitabine—prostate cancer	0.000589	0.000746	CcSEcCtD
Droperidol—Dermatitis—Capecitabine—prostate cancer	0.000588	0.000745	CcSEcCtD
Droperidol—Tachycardia—Doxorubicin—prostate cancer	0.000588	0.000744	CcSEcCtD
Droperidol—HTR2A—testis—prostate cancer	0.000582	0.028	CbGeAlD
Droperidol—Somnolence—Epirubicin—prostate cancer	0.000578	0.000733	CcSEcCtD
Droperidol—Hypotension—Doxorubicin—prostate cancer	0.000562	0.000713	CcSEcCtD
Droperidol—Dizziness—Prednisone—prostate cancer	0.00055	0.000697	CcSEcCtD
Droperidol—Somnolence—Doxorubicin—prostate cancer	0.000535	0.000678	CcSEcCtD
Droperidol—Rash—Prednisone—prostate cancer	0.000524	0.000664	CcSEcCtD
Droperidol—Dermatitis—Prednisone—prostate cancer	0.000524	0.000664	CcSEcCtD
Droperidol—Body temperature increased—Epirubicin—prostate cancer	0.000514	0.000652	CcSEcCtD
Droperidol—Hypersensitivity—Epirubicin—prostate cancer	0.000479	0.000607	CcSEcCtD
Droperidol—Body temperature increased—Doxorubicin—prostate cancer	0.000476	0.000603	CcSEcCtD
Droperidol—Hypersensitivity—Doxorubicin—prostate cancer	0.000444	0.000562	CcSEcCtD
Droperidol—Dizziness—Epirubicin—prostate cancer	0.00043	0.000545	CcSEcCtD
Droperidol—Rash—Epirubicin—prostate cancer	0.00041	0.00052	CcSEcCtD
Droperidol—Dermatitis—Epirubicin—prostate cancer	0.00041	0.000519	CcSEcCtD
Droperidol—Dizziness—Doxorubicin—prostate cancer	0.000398	0.000504	CcSEcCtD
Droperidol—Rash—Doxorubicin—prostate cancer	0.00038	0.000481	CcSEcCtD
Droperidol—Dermatitis—Doxorubicin—prostate cancer	0.000379	0.00048	CcSEcCtD
Droperidol—ADRA1A—Signaling Pathways—PRKCZ—prostate cancer	4.75e-05	0.000292	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CG—prostate cancer	4.74e-05	0.000291	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CALCA—prostate cancer	4.7e-05	0.000289	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PARP1—prostate cancer	4.68e-05	0.000288	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGFR4—prostate cancer	4.68e-05	0.000288	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CG—prostate cancer	4.64e-05	0.000285	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CALCA—prostate cancer	4.63e-05	0.000284	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CXCL12—prostate cancer	4.59e-05	0.000282	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PARP1—prostate cancer	4.58e-05	0.000282	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGFR4—prostate cancer	4.58e-05	0.000282	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CALCA—prostate cancer	4.53e-05	0.000279	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CXCL12—prostate cancer	4.52e-05	0.000278	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CXCL12—prostate cancer	4.42e-05	0.000272	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CG—prostate cancer	4.37e-05	0.000269	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CASP9—prostate cancer	4.32e-05	0.000266	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CG—prostate cancer	4.3e-05	0.000265	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CASP9—prostate cancer	4.25e-05	0.000262	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CD—prostate cancer	4.23e-05	0.00026	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CG—prostate cancer	4.21e-05	0.000259	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NGFR—prostate cancer	4.19e-05	0.000258	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PRKCQ—prostate cancer	4.19e-05	0.000258	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CD—prostate cancer	4.17e-05	0.000256	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CASP9—prostate cancer	4.17e-05	0.000256	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAP3K7—prostate cancer	4.14e-05	0.000255	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PRKCQ—prostate cancer	4.12e-05	0.000254	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NGFR—prostate cancer	4.12e-05	0.000254	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CD—prostate cancer	4.08e-05	0.000251	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAP3K7—prostate cancer	4.07e-05	0.000251	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PRKCQ—prostate cancer	4.04e-05	0.000248	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NGFR—prostate cancer	4.04e-05	0.000248	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAP3K7—prostate cancer	3.99e-05	0.000245	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGF10—prostate cancer	3.98e-05	0.000245	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ADRB2—prostate cancer	3.94e-05	0.000242	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGF10—prostate cancer	3.92e-05	0.000241	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—JAK2—prostate cancer	3.89e-05	0.000239	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ADRB2—prostate cancer	3.88e-05	0.000238	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—MAP2K1—prostate cancer	3.87e-05	0.000238	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CD—prostate cancer	3.84e-05	0.000236	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—VAV3—prostate cancer	3.84e-05	0.000236	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGF10—prostate cancer	3.84e-05	0.000236	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—JAK2—prostate cancer	3.82e-05	0.000235	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—MAP2K1—prostate cancer	3.81e-05	0.000234	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ADRB2—prostate cancer	3.8e-05	0.000233	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TGFBR2—prostate cancer	3.79e-05	0.000233	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CD—prostate cancer	3.78e-05	0.000233	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—VAV3—prostate cancer	3.78e-05	0.000232	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—JAK2—prostate cancer	3.74e-05	0.00023	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—MAP2K1—prostate cancer	3.73e-05	0.000229	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ITPR1—prostate cancer	3.73e-05	0.000229	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TGFBR2—prostate cancer	3.73e-05	0.000229	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CD—prostate cancer	3.7e-05	0.000228	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—VAV3—prostate cancer	3.7e-05	0.000228	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CB—prostate cancer	3.69e-05	0.000227	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ITPR1—prostate cancer	3.67e-05	0.000225	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TGFBR2—prostate cancer	3.65e-05	0.000224	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CB—prostate cancer	3.63e-05	0.000223	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ITPR1—prostate cancer	3.59e-05	0.000221	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IGF1R—prostate cancer	3.56e-05	0.000219	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CB—prostate cancer	3.56e-05	0.000219	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—CXCL8—prostate cancer	3.55e-05	0.000218	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—JAK2—prostate cancer	3.53e-05	0.000217	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IGF1R—prostate cancer	3.51e-05	0.000216	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—CXCL8—prostate cancer	3.49e-05	0.000215	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—JAK2—prostate cancer	3.47e-05	0.000214	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IGF1R—prostate cancer	3.43e-05	0.000211	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—CXCL8—prostate cancer	3.42e-05	0.00021	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—LPL—prostate cancer	3.42e-05	0.00021	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—JAK2—prostate cancer	3.4e-05	0.000209	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—IL2—prostate cancer	3.39e-05	0.000208	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PDGFRB—prostate cancer	3.38e-05	0.000208	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—LPL—prostate cancer	3.36e-05	0.000207	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CB—prostate cancer	3.35e-05	0.000206	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—IL2—prostate cancer	3.33e-05	0.000205	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PDGFRB—prostate cancer	3.33e-05	0.000205	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ITGB3—prostate cancer	3.3e-05	0.000203	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CB—prostate cancer	3.3e-05	0.000203	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—LPL—prostate cancer	3.29e-05	0.000202	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	3.27e-05	0.000201	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	3.26e-05	0.000201	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ITGB3—prostate cancer	3.25e-05	0.0002	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	3.23e-05	0.000199	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—CXCL8—prostate cancer	3.22e-05	0.000198	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ERBB3—prostate cancer	3.2e-05	0.000197	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGFR2—prostate cancer	3.19e-05	0.000196	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	3.18e-05	0.000195	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—CXCL8—prostate cancer	3.17e-05	0.000195	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ERBB3—prostate cancer	3.15e-05	0.000194	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGFR2—prostate cancer	3.14e-05	0.000193	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	3.1e-05	0.000191	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	3.08e-05	0.00019	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	3.08e-05	0.000189	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL2—prostate cancer	3.08e-05	0.000189	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TERT—prostate cancer	3.07e-05	0.000189	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL2—prostate cancer	3.03e-05	0.000186	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TERT—prostate cancer	3.02e-05	0.000186	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL2—prostate cancer	2.97e-05	0.000182	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TERT—prostate cancer	2.95e-05	0.000182	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—HIF1A—prostate cancer	2.93e-05	0.00018	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—HIF1A—prostate cancer	2.89e-05	0.000177	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—LEP—prostate cancer	2.86e-05	0.000176	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CAV1—prostate cancer	2.84e-05	0.000174	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	2.83e-05	0.000174	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—LEP—prostate cancer	2.82e-05	0.000173	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KDR—prostate cancer	2.8e-05	0.000173	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CAV1—prostate cancer	2.79e-05	0.000172	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KDR—prostate cancer	2.76e-05	0.00017	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—LEP—prostate cancer	2.76e-05	0.00017	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ESR1—prostate cancer	2.73e-05	0.000168	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CAV1—prostate cancer	2.73e-05	0.000168	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KDR—prostate cancer	2.7e-05	0.000166	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ESR1—prostate cancer	2.69e-05	0.000165	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—BAD—prostate cancer	2.67e-05	0.000164	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ESR1—prostate cancer	2.63e-05	0.000162	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—BAD—prostate cancer	2.62e-05	0.000161	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CG—prostate cancer	2.58e-05	0.000159	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APC—prostate cancer	2.58e-05	0.000159	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—BAD—prostate cancer	2.57e-05	0.000158	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EGF—prostate cancer	2.55e-05	0.000157	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IRS1—prostate cancer	2.55e-05	0.000157	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APC—prostate cancer	2.54e-05	0.000156	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	2.54e-05	0.000156	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EGF—prostate cancer	2.51e-05	0.000155	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IRS1—prostate cancer	2.51e-05	0.000155	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	2.49e-05	0.000153	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APC—prostate cancer	2.49e-05	0.000153	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—GSK3B—prostate cancer	2.48e-05	0.000152	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EGF—prostate cancer	2.46e-05	0.000151	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IRS1—prostate cancer	2.46e-05	0.000151	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—INS—prostate cancer	2.45e-05	0.00015	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—GSK3B—prostate cancer	2.44e-05	0.00015	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—INS—prostate cancer	2.41e-05	0.000148	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CREBBP—prostate cancer	2.4e-05	0.000147	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	2.39e-05	0.000147	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IGF1—prostate cancer	2.37e-05	0.000146	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CREBBP—prostate cancer	2.36e-05	0.000145	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—INS—prostate cancer	2.36e-05	0.000145	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—EGFR—prostate cancer	2.35e-05	0.000145	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IGF1—prostate cancer	2.33e-05	0.000143	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—EGFR—prostate cancer	2.32e-05	0.000142	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	2.31e-05	0.000142	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAP2K1—prostate cancer	2.29e-05	0.000141	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IGF1—prostate cancer	2.28e-05	0.00014	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CD—prostate cancer	2.27e-05	0.00014	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	2.27e-05	0.000139	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	2.25e-05	0.000138	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	2.25e-05	0.000138	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SERPINE1—prostate cancer	2.25e-05	0.000138	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	2.23e-05	0.000137	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—KRAS—prostate cancer	2.22e-05	0.000137	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.21e-05	0.000136	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	2.21e-05	0.000136	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	2.2e-05	0.000135	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	2.19e-05	0.000135	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—KRAS—prostate cancer	2.19e-05	0.000135	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGF2—prostate cancer	2.17e-05	0.000134	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	2.17e-05	0.000133	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	2.16e-05	0.000133	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NOS3—prostate cancer	2.14e-05	0.000132	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	2.14e-05	0.000132	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGF2—prostate cancer	2.14e-05	0.000132	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NOS3—prostate cancer	2.11e-05	0.00013	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGF2—prostate cancer	2.1e-05	0.000129	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—JAK2—prostate cancer	2.08e-05	0.000128	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NOS3—prostate cancer	2.07e-05	0.000127	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—JAK2—prostate cancer	2.05e-05	0.000126	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	2.04e-05	0.000126	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MDM2—prostate cancer	2.03e-05	0.000125	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	2.01e-05	0.000124	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—JAK2—prostate cancer	2.01e-05	0.000124	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ERBB2—prostate cancer	2.01e-05	0.000123	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MDM2—prostate cancer	2e-05	0.000123	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CB—prostate cancer	1.98e-05	0.000122	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ERBB2—prostate cancer	1.97e-05	0.000121	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.97e-05	0.000121	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.96e-05	0.000121	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	1.95e-05	0.00012	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.93e-05	0.000119	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.91e-05	0.000117	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CXCL8—prostate cancer	1.9e-05	0.000117	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CXCL8—prostate cancer	1.87e-05	0.000115	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN1B—prostate cancer	1.86e-05	0.000114	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—AKT1—prostate cancer	1.84e-05	0.000113	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.83e-05	0.000113	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	1.83e-05	0.000112	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CASP3—prostate cancer	1.82e-05	0.000112	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL2—prostate cancer	1.82e-05	0.000112	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL6—prostate cancer	1.81e-05	0.000111	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	1.81e-05	0.000111	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CASP3—prostate cancer	1.79e-05	0.00011	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.79e-05	0.00011	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL2—prostate cancer	1.79e-05	0.00011	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL6—prostate cancer	1.78e-05	0.000109	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCND1—prostate cancer	1.77e-05	0.000109	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.77e-05	0.000109	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CTNNB1—prostate cancer	1.76e-05	0.000108	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.75e-05	0.000108	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.75e-05	0.000108	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCND1—prostate cancer	1.74e-05	0.000107	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.74e-05	0.000107	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	1.73e-05	0.000106	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MMP9—prostate cancer	1.72e-05	0.000106	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN1A—prostate cancer	1.71e-05	0.000105	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PTEN—prostate cancer	1.71e-05	0.000105	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.71e-05	0.000105	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MMP9—prostate cancer	1.69e-05	0.000104	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.69e-05	0.000104	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	1.69e-05	0.000104	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PTEN—prostate cancer	1.68e-05	0.000104	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—AKT1—prostate cancer	1.67e-05	0.000103	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.66e-05	0.000102	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.65e-05	0.000102	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.65e-05	0.000101	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—AKT1—prostate cancer	1.64e-05	0.000101	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EP300—prostate cancer	1.63e-05	0.0001	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.61e-05	9.89e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EP300—prostate cancer	1.61e-05	9.87e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SRC—prostate cancer	1.59e-05	9.76e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.57e-05	9.67e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SRC—prostate cancer	1.56e-05	9.6e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—VEGFA—prostate cancer	1.55e-05	9.5e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—STAT3—prostate cancer	1.53e-05	9.41e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.53e-05	9.4e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1.52e-05	9.35e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—STAT3—prostate cancer	1.51e-05	9.26e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.49e-05	9.16e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.47e-05	9.07e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MYC—prostate cancer	1.42e-05	8.74e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TGFB1—prostate cancer	1.42e-05	8.72e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MYC—prostate cancer	1.4e-05	8.6e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.4e-05	8.58e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EGFR—prostate cancer	1.39e-05	8.55e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.37e-05	8.42e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.37e-05	8.42e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.37e-05	8.4e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.34e-05	8.24e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KRAS—prostate cancer	1.31e-05	8.08e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.29e-05	7.95e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KRAS—prostate cancer	1.27e-05	7.78e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.21e-05	7.42e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.19e-05	7.3e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TP53—prostate cancer	1.17e-05	7.18e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.16e-05	7.15e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TP53—prostate cancer	1.15e-05	7.07e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TP53—prostate cancer	1.12e-05	6.92e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL6—prostate cancer	1.07e-05	6.57e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL6—prostate cancer	1.05e-05	6.47e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL6—prostate cancer	1.03e-05	6.33e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AKT1—prostate cancer	9.86e-06	6.06e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AKT1—prostate cancer	9.7e-06	5.97e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AKT1—prostate cancer	9.5e-06	5.84e-05	CbGpPWpGaD
